VR Adviser, LLC Q1 2022 Filing
Filed May 16, 2022
Portfolio Value
$617.2B
Holdings
27
Report Date
Q1 2022
Filing Type
13F-HR
All Holdings (27 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACRSAclaris Therapeutics Inc | 4,563,962 | $78.7B | 12.75% | |
| 2 | TILInstil Bio Inc | 6,865,076 | $73.8B | 11.96% | |
| 3 | RLMDRelmada Therapeutics Inc | 2,270,072 | $61.3B | 9.93% | |
| 4 | TVTXTravere Therapeutics Inc | 1,994,997 | $51.4B | 8.33% | |
| 5 | GHRSGH Research PLC | 2,051,060 | $37.5B | 6.08% | |
| 6 | 1T7Tricida Inc | 4,494,851 | $36.9B | 5.99% | |
| 7 | VRDNViridian Therapeutics Inc | 1,852,919 | $34.3B | 5.55% | |
| 8 | MRNS*Marinus Pharmaceuticals Inc | 3,156,803 | $29.5B | 4.78% | |
| 9 | TCE2Celldex Therapeutics Inc | 865,116 | $29.5B | 4.77% | |
| 10 | WHWKAadi Bioscience Inc | 1,529,402 | $26.0B | 4.20% | |
| 11 | 290AChinook Therapeutics Inc | 1,283,821 | $21.0B | 3.40% | |
| 12 | LIANYLianBio | 5,378,341 | $20.0B | 3.23% | |
| 13 | VTGNUSDVistaGen Therapeutics Inc | 16,047,286 | $19.9B | 3.22% | |
| 14 | —Athira Pharma Inc | 1,000,000 | $13.5B | 2.19% | |
| 15 | CLDNEUREiger BioPharmaceuticals Inc | 1,469,767 | $12.2B | 1.98% | |
| 16 | NUVLNuvalent Inc | 803,951 | $11.2B | 1.81% | |
| 17 | GRPHGraphite Bio Inc | 1,612,617 | $8.2B | 1.33% | |
| 18 | PRVBUSDProvention Bio Inc | 1,118,653 | $8.2B | 1.33% | |
| 19 | COGTCogent Biosciences Inc | 1,088,817 | $8.2B | 1.32% | |
| 20 | ATYRaTyr Pharma Inc | 1,398,889 | $7.5B | 1.21% | |
| 21 | —Affimed NV | 1,428,571 | $6.2B | 1.01% | |
| 22 | —Sierra Oncology Inc | 162,479 | $5.2B | 0.84% | |
| 23 | ALTAltimmune Inc | 759,719 | $4.6B | 0.75% | |
| 24 | CNTACentessa Pharmaceuticals PLC | 411,361 | $3.7B | 0.60% | |
| 25 | CATBUSDAstria Therapeutics Inc | 538,999 | $3.6B | 0.59% | |
| 26 | AVTEAerovate Therapeutics Inc | 151,037 | $2.8B | 0.45% | |
| 27 | YB4PSavara Inc | 1,905,265 | $2.5B | 0.40% |